FDA Issues Guidance on NIR Analytical Procedures
The agency outlines recommendations for the development and submission of near infrared analytical procedures.
FDA has issued guidance detailing the agency’s recommendations for the development and submission of near infrared (NIR) analytical procedures. Also included in the guidance are recommendations for how to apply concepts from International Conference on Harmonization (ICH) Q2(R1) Validation of Analytical Procedures: Text and Methodology and PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance.
According to FDA, the recommendations in the guidance can be applied to other process analytical technologies including Raman, focused beam reflection measurement, particle imaging, and X-ray. The guidance, however, states that it only “pertains to the development and validation of NIR analytical procedures” and does not address set up, qualification, maintenance, or calibration of NIR instruments.
Source: FDA.gov
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
